NASDAQ:FREQ Frequency Therapeutics (FREQ) Stock Price, News & Analysis → Elon Musk’s PRIME is Set to Shock the World (From InvestorPlace) (Ad) Free FREQ Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.28▼$0.3250-Day Range$0.22▼$14.9852-Week Range$0.18▼$16.00Volume309,164 shsAverage Volume822,537 shsMarket Capitalization$10.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Frequency Therapeutics alerts: Email Address Ad InvestorPlaceElon Musk’s PRIME is Set to Shock the WorldMust-See: Elon's New Invention is Absolutely Insane When you click here and see what Elon Musk’s new invention does…You will NOT believe it. But Elon just tested this in a real human… And the result was mind-blowing.Click here for the full story… About Frequency Therapeutics Stock (NASDAQ:FREQ)Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.Read More Ad InvestorPlaceElon Musk’s PRIME is Set to Shock the WorldMust-See: Elon's New Invention is Absolutely Insane When you click here and see what Elon Musk’s new invention does…You will NOT believe it. But Elon just tested this in a real human… And the result was mind-blowing.Click here for the full story… FREQ Stock News HeadlinesMay 17 at 4:31 PM | msn.comThe Best Red Light Therapy Devices for Wrinkles, Acne, and Fine LinesMay 17 at 9:33 AM | msn.comDoes Red Light Therapy Stimulate Collagen?May 17 at 9:33 AM | finance.yahoo.comBayer’s non-hormonal therapy reduces hot flashes in Phase III trialsMay 16 at 3:10 PM | msn.comCognitive behavioral therapy might improve sleep quality in teens suffering from anxietyMay 16 at 3:10 PM | markets.businessinsider.comBuy Rating for Ovid Therapeutics Based on Promising Drug Trials and Strategic PartnershipsMay 11, 2024 | msn.comWhat is Vitamin IV therapy and how does it work?May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Trevi Therapeutics Amid Promising Clinical Advances and Solid Financial PositionMay 9, 2024 | finanznachrichten.deAkebia Therapeutics, Inc.: Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | uk.finance.yahoo.comQ1 2024 Viridian Therapeutics Inc Earnings CallMay 8, 2024 | msn.comXyloCor Therapeutics Announces Promising Results for Gene Therapy in Treating Refractory AnginaMay 8, 2024 | finance.yahoo.comResearchers hit ‘milestone’ in light therapy for spinal cord injury studyMay 7, 2024 | finance.yahoo.comKromaTiD Expands Their Gene Therapy Analytic Assay Suite with the Addition of GLP Genomic Integrity Karyotyping ServicesMay 6, 2024 | finanznachrichten.deIRLAB Therapeutics: IRLAB: Invitation to the Interim Report for Q1 2024 Presentation and WebcastMay 6, 2024 | finanznachrichten.deIRLAB Therapeutics: IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757May 4, 2024 | msn.comGene Therapy Allowing Heart to Grow New Blood Vessels Supported by Early DataMay 2, 2024 | msn.comGene therapy treatment increasing body's signal for new blood vessel growth shows promiseMay 2, 2024 | finance.yahoo.comTG Therapeutics Inc (TGTX) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue Growth ...May 2, 2024 | finance.yahoo.comThe World Market for Ovarian Cancer Drugs to 2030: Breakthroughs in Combination Drug Therapy Transforming Standards of CareMay 2, 2024 | msn.comDigital body language: How non-verbal communication works on social mediaMay 1, 2024 | msn.comNew mRNA cancer vaccine triggers fierce immune response to fight malignant brain tumorMay 1, 2024 | yahoo.comThe 10 best online therapy services for 2024May 1, 2024 | finance.yahoo.comNanoVibronix Announces PainShield Will Be Included in Department of Veteran Affairs’ FSS Contract AwardMay 1, 2024 | bizjournals.comG1 Therapeutics inks $135M deal with Boston firm for cancer treatmentApril 30, 2024 | nytimes.comWhy Is It So Hard to Shower When I’m Depressed?April 29, 2024 | forbes.comThe Best LED Face Masks To Target Fine Lines, Dark Spots And MoreSee More Headlines Receive FREQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Frequency Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today5/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FREQ CUSIPN/A CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees46Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-107.67% Return on Assets-61.40% Debt Debt-to-Equity RatioN/A Current Ratio5.81 Quick Ratio5.81 Sales & Book Value Annual Sales$14.07 million Price / Sales0.78 Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book0.15Miscellaneous Outstanding Shares36,520,000Free Float30,385,000Market Cap$10.94 million OptionableNot Optionable Beta0.84 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. David L. Lucchino (Age 53)Co-Founder, President, CEO & Director Comp: $1.02MMr. Richard J. Mitrano (Age 52)Vice President of Finance & Operations Mr. James P. AbelyAssociate General Counsel & SecretaryDr. John L. LaMattina Ph.D. (Age 73)Senior Advisor & Member of PCA Regenerative Medicine Advisory Board Key CompetitorsAvalo TherapeuticsNASDAQ:AVTXMIRA PharmaceuticalsNASDAQ:MIRAMoleculin BiotechNASDAQ:MBRXElevai LabsNASDAQ:ELABABVC BioPharmaNASDAQ:ABVCView All CompetitorsInsidersDavid L LucchinoSold 2,865 sharesTotal: $1,719.00 ($0.60/share)Richard J MitranoSold 227 sharesTotal: $143.01 ($0.63/share)David L LucchinoSold 2,895 sharesTotal: $1,881.75 ($0.65/share)Richard J MitranoSold 234 sharesTotal: $156.78 ($0.67/share)David L LucchinoSold 2,881 sharesTotal: $1,815.03 ($0.63/share) FREQ Stock Analysis - Frequently Asked Questions Should I buy or sell Frequency Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Frequency Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" FREQ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FREQ, but not buy additional shares or sell existing shares. View FREQ analyst ratings or view top-rated stocks. How were Frequency Therapeutics' earnings last quarter? Frequency Therapeutics, Inc. (NASDAQ:FREQ) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.57) by $0.16. What other stocks do shareholders of Frequency Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Frequency Therapeutics investors own include AbbVie (ABBV), Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD), Pfizer (PFE), Taiwan Semiconductor Manufacturing (TSM), Atreca (BCEL), Cidara Therapeutics (CDTX), Clovis Oncology (CLVS) and Chimerix (CMRX). When did Frequency Therapeutics IPO? Frequency Therapeutics (FREQ) raised $102 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 6,700,000 shares at a price of $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Mizuho Securities was co-manager. This page (NASDAQ:FREQ) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingObama’s Forever Term [exposed]Porter & Company4 Cryptos BETTER than BitcoinTrue Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMissed NVDA? Buy this AI stock NOWChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Frequency Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.